A 55-year-old female, with primary splenic angiosarcoma with metastatic lesions in liver, T-8 vertebra and left femur, status postsplenectomy, right hepatectomy and cholecystectomy, and multiple cycles of chemotherapy, was found to have a new 0.5 cm ill-defined attenuation focus in the body of pancreas on routine surveillance computed tomography (CT) scan. Follow-up of CT 2 months later revealed increase in size of the same mass to 0.8 cm [ Figure 1 ], worrisome of progressive metastatic lesion from angiosarcoma. The patient was referred for endoscopic ultrasound (EUS)-guided fine-needle aspiration and biopsy (FNAB). On EUS [ Figure 2 ], an 8 mm × 6 mm isoechoic rounded mass was seen in the pancreatic body. Transgastric EUS-guided fine-needle aspiration (two passes) and fine-needle core biopsy (two passes) were done using a 25 G, ProCore EUS needle (Cook). On cytology, specimens along with immunostains performed on the cell block sections showed that the neoplastic cells were positive for ERG and CD31 and focally/weakly positive for pan-cytokeratin. Immunohistochemical staining of the core biopsy revealed that the tumor cells were strongly positive for ERG (nuclear pattern), focally positive for CD31 and CD34, and negative for synaptophysin and chromogranin. This was consistent with metastatic angiosarcoma .
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Angiosarcomas are rare, malignant, and frequently fatal soft tissue tumors and may metastasize to almost all visceral organs including pancreas. Definitive diagnosis can be made only with immunochemistry, and hence, obtaining biopsy is of paramount importance. EUS-FNAB has previously been described for diagnosing angiosarcoma in suprarenal gland [1] and spleen [2] in two prior case reports. To our knowledge, we present the first case of EUS-FNAB use for diagnosis of angiosarcoma within the pancreas. Primary angiosarcoma in pancreas may present as acute pancreatitis and diagnosis may be missed if biopsy is not performed as described by Csiszkó et al. [3] and Seth et al. [4] separately in their case reports. We recommend keeping angiosarcoma as a possible rare differential while evaluating pancreatic masses and
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